Dolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority ODYSSEY trial

BACKGROUND: Dolutegravir-based antiretroviral therapy is a preferred first-line treatment for adults and children living with HIV; however, very little pharmacokinetic data for dolutegravir use are available in young children. We therefore aimed to evaluate dolutegravir dosing and safety in children...

Descripción completa

Detalles Bibliográficos
Autores principales: Waalewijn, Hylke, Chan, Man K, Bollen, Pauline D J, Mujuru, Hilda A, Makumbi, Shafic, Kekitiinwa, Adeodata R, Kaudha, Elizabeth, Sarfati, Tatiana, Musoro, Godfrey, Nanduudu, Annet, Lugemwa, Abbas, Amuge, Pauline, Moore, Cecilia L, Rojo, Pablo, Giaquinto, Carlo, Colbers, Angela, Gibb, Diana M, Ford, Deborah, Turkova, Anna, Burger, David M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9046096/
https://www.ncbi.nlm.nih.gov/pubmed/35189082
http://dx.doi.org/10.1016/S2352-3018(21)00292-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9046096/
https://www.ncbi.nlm.nih.gov/pubmed/35189082
http://dx.doi.org/10.1016/S2352-3018(21)00292-7

Ejemplares similares